Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.49 |
| ▸ | CNR1 | P21554 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5541139 | 0.88 | CNR2 (0.50) | CNR2CNR1BRD4TLR2DRD4 | |
| SCHEMBL5547150 | 0.87 | CNR2 (0.49) | CNR2CNR1BRD4TLR2 | |
| SCHEMBL5547157 | 0.87 | CNR2 (0.49) | CNR2CNR1BRD4TLR2 | |
| SCHEMBL5541161 | 0.85 | CNR2 (0.42) | CNR2CNR1RAB9ACCR3NPY5R | |
| SCHEMBL5547227 | 0.84 | GRIN1 (0.46) | CNR2CNR1BRD4TLR2 | |
| SCHEMBL5541062 | 0.81 | KDM4E (0.44) | CNR2CNR1TLR2 | |
| SCHEMBL5546823 | 0.80 | KDM4E (0.49) | CNR2CNR1TLR2 | |
| SCHEMBL5546512 | 0.80 | GRIN1 (0.45) | CNR2 | |
| SCHEMBL5545820 | 0.79 | CNR1 (0.49) | CNR2CNR1BRD4 | |
| SCHEMBL5545819 | 0.79 | CNR2 (0.52) | CNR2CNR1RAB9ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | CNR2 4810/4885CNR1 4670/4885RAB9A 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.